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Objective Percutaneous coronary intervention in patients
with a history of previous coronary artery bypass grafting
(CABG) is associated with an increased rate of subsequent
adverse events compared to those without prior CABG. We
evaluated the impact of utilizing the sirolimus-eluting stent
(SES) in this high-risk population.
Methods Since April 2002, SES implantation was utilized
as the default strategy for all percutaneous procedures in
our hospital. Consecutive patients with a history of
previous CABG and de novo lesions (n=47) treated
exclusively with SES, were compared to 66 patients who
received bare stents in the 6-month period just before SES
introduction.
Results There were no significant differences between the
groups (SES and bare stent) with respect to baseline
clinical or lesion characteristics. The only difference
between the groups related to the nominal diameter of
stent utilized, which was smaller in the SES group than the
bare stent group. (The maximum diameter of SES available
was 3.0mm). At 1 year, the cumulative incidence of major
adverse events (defined as death, myocardial infarction, or
target vessel revascularization) was significantly lower in
the SES group than the bare stent group [8.5 versus 30.3%,
hazard ratio 0.37 (95% confidence interval 0.15–0.91);
P=0.03].
Conclusions The utilization of the sirolimus-eluting stent
for percutaneous intervention in a high-risk population with
a history of previous CABG surgery is associated with a
significant reduction in the rate of major adverse cardiac
events at 1 year. Coron Artery Dis 15:171–175 c 2004
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Introduction
More than 300 000 people undergo coronary artery bypass
graft (CABG) surgery every year in the USA alone, yet
CABG is not a definitive therapy and patients continue to
have considerable cardiovascular morbidity and mortality.
Recurrence of ischaemia and angina relates to either
progression of native vessel atherosclerosis, or failure of
the bypass grafts themselves. Indeed, angiographic
studies have shown that by 10–12 years, 75–79% vein
grafts are occluded or severely diseased [1,2]. Further-
more, studies have also suggested that following bypass
implantation, atherosclerosis within the native vessels
may actually progress more rapidly compared to vessels in
the same patient that were not grafted [3,4]. In the large
Coronary Artery Surgery Study (CASS) of more than 9500
patients, angina recurred in 24% within the first year and
in 40% by the sixth year [5]. Therefore, an increasing
number of people with a history of previous CABG are
being considered for further revascularization therapy.
Repeat CABG surgery is associated with a higher
mortality than the first operation, and is associated with
less symptomatic improvement [6,7]. Percutaneous
revascularization is therefore an attractive alternative
strategy. However, following percutaneous coronary inter-
vention (PCI), patients with prior CABG have been
shown to have an increased combined risk of death and
myocardial infarction [8–13]. They have a higher risk
profile than those without previous CABG, tend to be
older, and have more extensive vessel disease. Further-
more, intervention with stent implantation within venous
bypass grafts is, in itself, is associated with a high
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subsequent rate of restenosis of 37–53% [14,15]. Drug-
eluting stents have been shown to be highly successful in
reducing restenosis in native coronary disease in a select
patient population [16,17]. The present study evaluates
the sirolimus-eluting stent (SES) for percutaneous
intervention in a high-risk population of patients with
previous CABG, compared to those treated in the
preceding 6 months with bare metal stents (BMS).
Materials and study population
From April 2002, all percutaneous coronary interventions
at our centre were done with a policy of SES usage,
irrespective of clinical presentation or lesion morphol-
ogy—further details of the methodology are described
elsewhere [18,19]. All procedures were performed with
standard interventional techniques except with the use of
SES as the device of choice. The SESs were available in
lengths between 8 and 33mm, and diameters of between
2.25 and 3.0mm. All patients were treated with long-term
aspirin therapy and received a loading dose of 300mg
clopidogrel followed by a daily dose of 75mg for at least 3
months. The procedural utilization of glycoprotein IIb/
IIIa inhibitor therapy and distal protection devices was at
the discretion of the operator. Angiographic success was
defined as a final diameter stenosis from an on-line
quantitative coronary angiography measurement of 50%.
The current study cohort comprises of 47 patients with a
previous history of CABG who were treated for de novo
lesions(s) solely with SES. This group was then compared
with a control group (n=66) comprised of those patients
who had been treated similarly in the preceding 6 months
though with bare stent implantation. The protocol was
approved by the local ethics committee and is in
accordance with the principles of Good Clinical Practice
for Trials of Medicinal Products in the European
Community and the Declaration of Helsinki. All patients
signed a written informed consent.
Follow-up
Patients were followed up prospectively and evaluated
for survival free of major adverse cardiac events
(MACE). Major adverse cardiac events were pre-defined
as: (1) death, (2) non-fatal myocardial infarction (AMI),
or (3) repeat target vessel revascularization. The
diagnosis of myocardial infarction required an elevation
of creatine kinase levels to twice the upper limit of
normal, together with a rise in creatine kinase-MB
fraction. Target vessel revascularization (TVR) was
defined as re-intervention in the treated vessel.
Statistical analysis
Discrete variables are presented as percentages and
compared with Fisher exact tests. Continuous variables
are expressed as mean± standard deviation and com-
pared with Student’s t-test. The MACE-free survival
curves were calculated according to the Kaplan–Meier
method. Hazard ratios (and their 95% confidence
intervals) of adverse events were calculated by Cox
proportional hazard models. A P<0.05 was considered
statistically significant.
Results
Baseline patient demographics and procedural data are
presented in Tables 1 and 2 respectively. Notably,
patients were relatively old with a mean age of 69 years
in the bare stent cohort, and 68 years in the SES group. In
addition, there was a high rate of multivessel disease
(95.5% in the bare stent group, 91.5% in the SES group),
and approximately one-fifth of the patients (19.7% in the
bare stent group, 21.3% in the SES group) had diabetes
mellitus. There were no significant differences between
the two groups treated with either bare stents or SES,
except in the mean nominal diameter of stent utilized,
which was smaller in the SES group. Intervention
within native coronary arteries only, occurred in
59.9% of the bare stent group, and 63.8% of the SES
group. The angiographic success rate in both groups was
high at > 97%.
At follow-up, there were no episodes of either acute or
sub-acute stent thrombosis in either cohort. Table 3
presents the Kaplan–Meier estimates of the rate of major
adverse cardiac events of the two groups at 1 year. There
is a significantly lower rate of events in the SES group,
predominantly related to a reduced need for repeat target
vessel revascularization (TVR). At 1 year, one patient
treated with SES (2.1%) required TVR for restenosis of a
stent within a saphenous vein graft (SVG), giving an
overall TVR rate within this population of 6.3% (one out
of the 16 survivors). This compares with 15 patients
(22.7%) treated with BMS who required TVR. Of these
15 patients, nine underwent TVR for in-stent restenosis
within a native vessel. The remaining six underwent TVR
Table 1 Baseline patient demographics
Bare stent
n=66
SES group
n=47
P value
Male sex (%) 66.7 70.3 0.5
Mean age (years) 69.0±10.9 68.0±9.0 1.0
Current smoker (%) 16.7 10.6 0.4
Diabetes mellitus (%) 19.7 21.3 1.0
Hypertension (%) 54.5 61.7 0.6
Hypercholesterolaemia (%) 83.3 89.4 0.6
Previous myocardial infarction (%) 47.7 31.9 0.2
Previous percutaneous coronary
intervention (%)
39.4 42.6 0.9
Presence of multivessel disease (%) 95.5 91.5 0.5
Clinical presentation
Stable angina (%) 48.5 63.8 0.2
Unstable angina (%) 43.9 34.0 0.4
Acute myocardial infarction (%) 7.6 2.1 0.4
Use of glycoprotein IIb/IIIa
inhibitor (%)
36.4 21.3 0.1
SES, sirolimus-eluting stents.
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(one re-do CABG) for restenosis within a SVG giving an
overall TVR rate within this population of 25.0% (six out
of the 24 survivors). The Kaplan–Meier curves for the
cumulative incidence of major adverse cardiac events are
presented in Figure 1.
Discussion
Previous data show that percutaneous intervention with
bare stents in patients with a history of previous CABG, is
associated with an increased rate of MACE compared to
those without prior CABG [8–13]. This relates, at least in
part, to the association of this group of patients with an
adverse risk profile as patients tend to be older, and have
a higher prevalence of diabetes, and multivessel disease
[8–13]. Moreover, this increase in MACE is evident
whether patients are being treated in the context of
either stable angina, or an acute coronary syndrome
[8–13]. However, we have demonstrated that in a
consecutive series of patients with previous CABG
treated with PCI and stent implantation, the utilization
of the sirolimus-eluting stent significantly reduces the
rate of MACE compared to those treated with bare metal
stents.
It is 20 years since Douglas et al., demonstrated the
feasibility of PCI in patients with a history of CABG [20].
More recently, the AWESOME randomized trial and
registry demonstrated that at 3 years, the overall survival
of patients with previous CABG and medically refractory
angina was similar whether treated with either PCI or
repeated CABG [21]. Moreover, when given the choice of
PCI or a repeat CABG, the majority of patients preferred
the former option. The investigators concluded that PCI
may be the preferred revascularization strategy.
In the present study, 40.9% in the bare stent group, and
36.2% of the SES group underwent intervention within at
least one bypass graft. Compared to native vessels,
percutaneous revascularization of diseased saphenous
vein grafts is hampered by an increased rate of adverse
events thereby contributing to the worse outcome of
post-CABG patients. Procedural complications may relate
to distal embolization of friable material within the graft,
and at follow-up, grafts are subject to an increased rate of
restenosis. Historically, results of balloon-only therapy
were disappointing [22–24]. In one study of 454 patients,
procedural success was 90%, with a 5-year MACE-free
survival of only 26% [24]. Subsequently, a randomized
trial demonstrated the benefit of stenting over balloon-
only angioplasty. At 6-months, the rate of survival free
from either death, myocardial infarction, repeat CABG, or
target lesion revascularisation was 73% in the stented
Table 2 Procedural data
Bare stent
n=66
SES group
n=47
P value
Treated vessel
Left anterior descending (%) 34.8 42.6 0.4
Left circumflex (%) 33.3 29.8 0.8
Right coronary artery (%) 27.3 17.0 0.3
Left main coronary (%) 15.2 10.6 0.6
Bypass graft (%) 40.9 36.2 0.7
Use of a distal protection device (% of
those with graft intervention)
5 (18.5) 6 (35.3) 0.3
Lesion type
Type A (%) 16.7 20.6 0.6
Type B1 (%) 24.2 29.8 0.5
Type B2 (%) 59.1 50.4 0.3
Type C (%) 40.9 36.2 0.7
Mean number of stents 2.1±1.4 1.9 ±0.9 0.7
Mean nominal diameter of stent (mm) 3.3±0.6 2.8 ±0.3 <0.001
Mean length of stents per patient (mm) 35.1±24.7 32.6 ±22.1 0.6
Angiographic success (%) 98.5 97.9 1.0
SES, sirolimus-eluting stents.
Table 3 Kaplan–Meier estimates of major adverse events at 1 year
Bare stents SES HR 95% CI p value
Death (%) 6.1 2.1 0.34 0.04–3.09 0.3
Death or myocardial infarction (%) 10.6 6.4 0.80 0.24–2.71 0.7
Target vessel revascularisation (%) 23.0 2.1 0.23 0.07–0.80 0.02
Any event (%) 30.3 8.5 0.37 0.15–0.91 0.03
HR, hazard ratio; SES, sirolimus-eluting stents; CI, confidence interval.
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Kaplan–Meier curves for the cumulative incidence of major adverse
events at 1 year, for patients with a history of previous coronary artery
bypass surgery treated with sirolimus-eluting stent implantation versus
bare stent implantation.
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group versus just 58% in the balloon-only group
(P=0.03) [15]. However, the angiographic restenosis
rate remained high (37 versus 46% respectively,
P=0.24).
The major limitation of PCI has always been the
development of in-stent restenosis and subsequent need
for repeat revascularization. In particular, restenosis rates
utilizing bare stents within saphenous venous bypass
grafts range between 37–53% [14,15]. Intervention solely
within native vessels was undertaken in 59.9% of the bare
stent group, and 63.8% of the SES group. However, the
type of native vessel disease manifested in a population
with a history of previous CABG can be difficult to
effectively treat percutaneously; lesions may be ostial, or
chronically occluded, or the disease may be diffuse and
the arteries small and calcified. These features, together
with the increased prevalence of diabetes in these
patients, tend to increase the risk of developing rest-
enosis [25,26].
Studies evaluating the SES have demonstrated low rates
of restenosis compared with bare stents when used in
relatively simple lesions [16,17]. The current study
evaluated the results of PCI in a high-risk population
with a history of previous CABG. Both cohorts were
comparable with respect to baseline clinical and lesion
characteristics, and all procedures were carried out as a
consecutive series, in a single centre by the same
operators. The only difference between the groups was
a significantly smaller mean nominal diameter of stent
utilized in the SES group. This is likely to reflect the fact
that the maximum nominal diameter of SES available was
3.0mm [27] (though post-dilatation was freely allowed)
which is often small particularly within venous bypass
grafts. A smaller stent (associated with a smaller minimal
lumen diameter) is more likely to be associated with
subsequent restenosis [28], which might have tended
towards an increased need for target vessel revasculariza-
tion in the SES group. However, at 1 year, those treated
with SES had a significantly lower rate of MACE
compared to those patients treated with bare stent
implantation, predominantly related to a reduction in the
need for repeat target vessel revascularization.
The present study is limited as it evaluated only a small
cohort of patients with de novo lesions, and there was no
routine angiographic follow-up. In particular, the number
of patients who underwent saphenous vein graft inter-
vention was small. In addition, the study was not
randomized, and used a retrospective comparative
population. However, the same operators and interven-
tional techniques were utilized, and our study accurately
reflects the ‘real world’ practice of interventional
cardiology. We have clearly demonstrated the applicability
of the sirolimus-eluting stent in reducing the subsequent
rate of adverse cardiac events at 1 year, in a high-risk
population with a history of previous coronary artery
bypass graft surgery.
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